

Table . Comparison of patients undergoing 2nd RB according to development of renal failure

	Renal failure (n=26)	No renal failure (n=69)*	p
Total FU (years), mean (SD)	21 (10.4)	16.5 (9.39)	0.002
SCr (mg/dl) at 2° RB, mean (SD)	1.7 (1)	0.98 (0.35)	0.001
Proteinuria (g/24h) at 2° RB, mean (SD)	4.7 (3.9)	2.99 (2.63)	0.022
Class IV and IV+V at 2° RB, %	76.9	54.5	0.07
Hypertension at onset, %	84.6	32.4	<0.001
HCO intake at 2° RB, %	9.5	52	<0.001
Glucocorticoids at 2° RB %	84	87	ns
Immunosuppressants at 2° RB %	40	58	ns
AI at onset, mean (SD)	7.14 (3.95)	7.02 (3.86)	ns
AI at 2° RB, mean (SD)	5.37 (4.12)	4.02 (3.71)	ns
CI at onset, mean (SD)	2.05 (1.88)	1.56 (1.64)	ns
CI at 2° RB, mean (SD)	3.87 (3.08)	3.52 (2.16)	ns
Years between 2° RB and end of FU, mean (SD)	14.1 (10.5)	9.3 (8.84)	ns

*Group 1 excluded

RB, renal biopsy; AI, activity index; CI, chronicity index; SCr serum creatinine; FU, follow-up; SD, standard deviation.

Disclosure of Interests: Mariele Gatto Speakers bureau: GSK, Francesca Saccon: None declared, Francesca Radice: None declared, Paolo Gilles Vercelloni: None declared, Renato Alberto Sinico: None declared, Giulia Frontini: None declared, Valentina Binda: None declared, Piergiorgio Messa: None declared, Federico Alberici: None declared, Gabriella Moroni: None declared, Andrea Doria Consultant of: GSK, Pfizer, Abbvie, Novartis, Ely Lilly, Speakers bureau: UCB pharma, GSK, Pfizer, Janssen, Abbvie, Novartis, Ely Lilly, BMS
DOI: 10.1136/annrheumdis-2020-eular.3523

THU0250 URINE AND SERUM S100 PROTEINS ASSOCIATE WITH LUPUS NEPHRITIS AND RESPONSE TO TREATMENT

J. Davies¹, A. Midgley¹, S. Donohue¹, I. N. Bruce², M. Beresford¹, C. Hedrich¹ on behalf of the MRC MASTERPLANS and BILAG-BR Consortia. ¹University of Liverpool, Institute of Translational Medicine, Department of Women's and Children's Health, Liverpool, United Kingdom; ²University of Manchester, Arthritis Research UK Epidemiology Unit, Faculty of Biology Medicine and Health, Manchester, United Kingdom

Background: Systemic lupus erythematosus (SLE) is a systemic autoimmune/inflammatory disease. Approximately 30% of SLE patients develop lupus nephritis (LN) that affects treatment and prognosis. Easily accessible biomarkers do not exist to reliably predict renal disease¹. Recently, calcium-binding S100 proteins have been suggested as biomarkers in systemic inflammatory conditions, including SLE^{2,3}.

Objectives: The MASTERPLANS Consortium aims to identify indicators of treatment responses in SLE. This study tested the applicability of S100 proteins in serum and urine as biomarkers for disease activity and response to treatment with rituximab in LN.

Methods: S100A8/A9 and S100A12 proteins were quantified in the serum and urine of 243 SLE patients from the BILAG-BR study and 48 matched controls using MSD technology to determine whether they perform as biomarkers for active LN (n=85 SLE patients) and/or may be used to predict response to treatment with rituximab. Renal disease activity and response to treatment was based on BILAG-BR scores and changes in response to treatment^{4,5}.

Results: Serum S100A12 (p<0.001), and serum and urine S100A8/A9 (p<0.001) are elevated in SLE patients. While serum and urine S100 levels do not correlate with global SLE disease activity (SLEDAI), levels in urine and urine/serum ratios are elevated in SLE patients with active LN (S100A8/A9: urine p>0.005, urine/serum p<0.05; S100A12: urine p<0.05, serum/urine p<0.005). S100 proteins perform better as biomarkers for active LN involvement in SLE patients positive for anti-dsDNA antibodies. Lastly, binary logistic regression and AUC analysis suggests the combination of serum S100A8/A9 and S100A12 to predict response to RTX treatment in LN after 6 months.

Conclusion: Findings from this study show promise for clinical application of S100 proteins to predict active renal disease in SLE and response to treatment with rituximab. Significantly overlapping values between groups currently prohibit the definition of cut-off values and prospective studies are required to validate findings.

References:

- [1] Reppe Moe SE, et al. Assessing the relative impact of lupus nephritis on mortality in a population-based systemic lupus erythematosus cohort. *Lupus*. 2019;28(7):818-825.
- [2] Austermann J, et al. S100 proteins in rheumatic diseases. *Nat Rev Rheumatol*. 2018;14(9):528-541.

- [3] Tydén H, et al. Pro-inflammatory S100 proteins are associated with glomerulonephritis and anti-dsDNA antibodies in systemic lupus erythematosus. *Lupus*. 2017;26(2):139-149.
- [4] Yee CS, et al. Numerical scoring for the BILAG-2004 index. *Rheumatology*. 2010; 49(9):1665-1669.
- [5] McCarthy et al. Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: Results from the british isles lupus assessment group biologics register. *Rheumatol*. 2018;57(3):470-479.

Acknowledgments: Clinical information and serum/urine samples from SLE patients were provided by BILAG-BR centres.

Disclosure of Interests: Jennifer Davies: None declared, Angela Midgley: None declared, Sean Donohue: None declared, Ian N. Bruce Grant/research support from: Genzyme Sanofi, GSK, and UCB, Consultant of: Eli Lilly, AstraZeneca, UCB, Ilto, and Merck Serono, Speakers bureau: UCB, Michael Beresford: None declared, Christian Hedrich Grant/research support from: Research grant support from Novartis (Molecular pathophysiology of psoriasis), Speakers bureau: Speaker honoraria from Roche (pathophysiology of polyarticular JIA and systemic JIA); involved in advisory boards for Novartis (systemic JIA and IL-1 mediated diseases).

DOI: 10.1136/annrheumdis-2020-eular.1180

THU0251 IMMUNOPHENOTYPIC CLUSTERS OF SLE PATIENTS REVEAL SUBGROUPS WITH SEVERE DISEASE RESISTANT TO CONVENTIONAL THERAPY

A. Psarras¹, D. Li², A. Alase¹, Z. Wigston¹, I. Bruce³, N. Mchugh², E. Vital¹.

¹University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom; ²University of Bath, Bath, United Kingdom; ³University of Manchester, Manchester, United Kingdom

Background: Biomarkers to predict response to rituximab include plasmablasts and, in the current MASTERPLANS consortium, Sm/U1RNP antibodies and high expression of IFN Score B (a subset of interferon-stimulated genes that predict more clinical outcomes than a classic interferon signature). The relationships amongst these biomarkers and their association with response to conventional therapies are less well described.

Objectives: To analyse the inter-relationships amongst immune biomarkers in two independent SLE cohorts in association with disease activity and stage of therapeutic pathway.

Methods: CONVAS is a cohort of unselected SLE patients; data available include current and historic disease activity, use of biologic therapy, flow cytometry, gene expression (IFN Score A and IFN Score B), and immunoprecipitation for autoantibodies (n=91). BILAG-BR is a British registry study for SLE patients commencing biologics; data available include current and historic disease activity, gene expression (IFN Score A and IFN Score B) and immunoprecipitation for autoantibodies (n=112). In both cohorts, biologics were only prescribed to patients with active disease (BILAG 1 x A or 2 x B) and failure of either cyclophosphamide or mycophenolate. Given the mixture of continuous and categorical variables, data were clustered using Gower distance and Partitioning Around Medoids. K was chosen using silhouette coefficient and clusters visualised with t-Distributed Stochastic Neighbor Embedding (t-SNE).

Results: There were 6 clusters. In rituximab-naïve patients:

1. Sm/U1RNP+, Ro60-, highest IFN Score A, low CD4⁺ T cells, low NK cells, high plasmablasts
2. Sm/U1RNP-, Ro60+, medium IFN Score A, low CD4⁺ T cells, high NK cells, high plasmablasts
3. Sm/U1RNP-, Ro60-, lowest IFN Score A, high CD4⁺ T cells, low NK cells, low plasmablasts

Other antibody subtypes and flow cytometric markers did not improve the accuracy of clustering. In rituximab-treated patients, 3 equivalent clusters for antibody subtypes and IFN Score A were observed but differentiated due to flow cytometry findings, as expected after rituximab treatment. Overall, the patients in the cluster defined by Sm/U1RNP antibodies and high IFN Score A were notable for a higher rate of prior disease activity in the renal, neurological and general BILAG domains (Table 1).

Table 1 : Clinical features in unselected SLE patients (CONVAS)

System affected (ever)	Sm/U1RNP & high IFN Score A (n=27)	Other (n=92)	p value
General	14/27 (52%)	24/92 (26%)	0.02
Mucocutaneous	23/27 (85%)	73/92 (79%)	0.50
Neuro	10/27 (37%)	17/92 (19%)	0.04
MSK	25/27 (93%)	83/92 (90%)	0.71
Cardiorespiratory	9/27 (33%)	20/92 (22%)	0.22
Renal	12/27 (44%)	15/92 (16%)	0.005
Haematology	25/27 (93%)	67/92 (73%)	0.03